The global veterinary vaccines market has reached a remarkable milestone in 2026, valued at $16.04 billion and projected to grow at an impressive 6.99% CAGR to reach $24.15 billion by 2032. This unprecedented growth is fueled by groundbreaking innovations including Elanco’s newly approved TruCan Ultra CIV canine influenza vaccine and Befrena (tirnovetmab) for allergic dermatitis, alongside Merck’s revolutionary RNA-based Nobivac NXT technology.
The industry witnessed over 15 major approvals in 2025 alone, spanning critical disease categories from parvovirus and avian influenza to emergency screwworm treatments. Our interactive Veterinary Vaccines Dashboard 2026 provides real-time insights into these developments, featuring disease-wise vaccine analytics, market projections, and direct links to official sources from USDA, EMA, and leading veterinary journals.
Whether you’re a veterinary professional, animal health researcher, or industry stakeholder, this comprehensive resource tracks the latest AAHA vaccination guidelines, regulatory updates, and strategic mergers like the $3.5 billion Covetrus-MWI Animal Health deal that’s reshaping distribution networks across companion and production animal sectors.